share_log

Needham Maintains Buy on KalVista Pharma, Lowers Price Target to $32

Needham Maintains Buy on KalVista Pharma, Lowers Price Target to $32

Needham维持KalVista Pharma的买入评级,将目标价下调至32美元。
Benzinga ·  07/12 05:37

Needham analyst Serge Belanger maintains KalVista Pharma (NASDAQ:KALV) with a Buy and lowers the price target from $35 to $32.

Needham分析师Serge Belanger维持对KalVista Pharma(纳斯达克股票代码:KALV)的买入评级并将目标价格从35美元下调至32美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发